La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Avalo Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Avalo Therapeutics..

Avalo Therapeutics (NASDAQ:AVTX) Azioni, Catena delle Opzioni

Avalo Therapeutics

Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Avalo Therapeutics Inc

Avantium NV

American Coastal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.35 by 54.29 percent. The company reported quarterly sales of $82.136 million which missed the analyst consensus estimate of $84.514 million by 2.81 percent. This is a 47.18 percent increase over sales of $55.808 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

ACIC

American Coastal Q3 2024 Adj. EPS $0.54 Beats $0.35 Estimate, Sales $82.136M Miss $84.514M Estimate

Veeco Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VECO#NASDAQ">VECO</a>) is looking for Q4 Adj EPS of $0.35-0.45 vs $0.46 analyst estimate. seessales of $165.000 million-185.000 million vs $182.98 million estimate.

Guidance

VECO

Veeco Instruments Sees Q4 Adj EPS $0.35-0.45 vs $0.46 Est; Sees Sales $165.000M-185.000M vs $182.98M Est

Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) reported quarterly losses of $(0.06) per share. This is a 40 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $101.000 thousand which missed the analyst consensus estimate of $300.000 thousand by 66.33 percent. This is a 100.26 percent increase over sales of $50.435 thousand the same period last year.

QUBT

Quantum Computing Q3 2024 GAAP EPS $(0.06) Up From $(0.10) YoY, Sales $101.000K Miss $300.000K Estimate

Sterling Infrastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>) raises FY2024 GAAP EPS guidance from $5.60-5.75 to $5.85-6.00 vs $5.67 analyst estimate. Narrows FY2024 sales outlook from $2.15 billion-2.23 billion to $2.15 billion-2.17 billion vs $2.17 billion estimate.

STRL

Sterling Infrastructure Raises FY2024 GAAP EPS Guidance from $5.60-5.75 to $5.85-6.00 vs $5.67 Est; Narrows FY2024 Sales Guidance from $2.15B-2.23B to $2.15B-2.17B vs $2.17B Est

Tenaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TS#NYSE">TS</a>) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $0.66 by 22.73 percent. The company reported quarterly sales of $2.915 billion which beat the analyst consensus estimate of $2.771 billion by 5.20 percent. This is a 9.98 percent decrease over sales of $3.238 billion the same period last year.

Tenaris Q3 2024 Adj. EPS $0.81 Beats $0.66 Estimate, Sales $2.915B Beat $2.771B Estimate

Sinclair Broadcast Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) reported quarterly earnings of $1.43 per share which beat the analyst consensus estimate of $0.98 by 45.92 percent. This is a 293.24 percent increase over losses of $(0.74) per share from the same period last year. The company reported quarterly sales of $917.00 million which missed the analyst consensus estimate of $923.00 million by 0.65 percent. This is a 19.56 percent increase over sales of $767.00 million the same period last year.

SBGI

Sinclair Broadcast Group Q3 EPS $1.43 Beats $0.98 Estimate, Sales $917.00M Miss $923.00M Estimate

DoubleVerify Sees Q4 2024 Revenue $194M-$200M Vs $204.7M Estimate; Sees FY24 Revenue $660M-$666M Vs $670.45M Estimate

Ameren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEE#NYSE">AEE</a>) reported quarterly earnings of $1.87 per share which missed the analyst consensus estimate of $1.93 by 3.11 percent. This is unchanged from the same period last year. The company reported quarterly sales of $2.17 billion which met the analyst consensus estimate. This is a 5.49 percent increase over sales of $2.06 billion the same period last year.

Ameren Q3 Adj $1.87 Misses $1.93 Estimate, Sales $2.17B Inline

WIIM

BMBL

Bumble shares are trading higher following a Q3 revenue beat.

Joby Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. The company reported quarterly sales of $28.000 thousand which missed the analyst consensus estimate of $43.000 thousand by 34.88 percent.

JOBY

Joby Aviation Q3 2024 GAAP EPS $(0.21) Misses $(0.19) Estimate, Sales $28.000K Miss $43.000K Estimate

Primerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRI#NYSE">PRI</a>) reported quarterly earnings of $5.16 per share which beat the analyst consensus estimate of $4.81 by 7.28 percent. The company reported quarterly sales of $774.13 million which beat the analyst consensus estimate of $745.32 million by 3.87 percent. This is a 10.99 percent increase over sales of $697.50 million the same period last year.

Primerica Q3 2024 Adj EPS $5.16 Beats $4.81 Estimate, Sales $774.13M Beat $745.32M Estimate

Superior Gr of Cos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGC#NASDAQ">SGC</a>) affirms FY2024 GAAP EPS guidance from $0.73-0.79 to $0.73-0.79 vs $0.74 analyst estimate. Affirms FY2024 sales outlook from $563.00 million-570.00 million to $563.00 million-570.00 million vs $564.22 million estimate.

Superior Gr of Cos Affirms FY2024 GAAP EPS Guidance to $0.73-0.79 vs $0.74 Est; Affirms FY2024 Sales Guidance to $563.00M-570.00M vs $564.22M Est

Arm Holdings Plc &#8211; ADR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) reported second-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the <a href="https://www.benzinga.com/pressreleases/24/11/b41786531/arm-holdings-plc-reports-results-for-the-second-quarter-of-the-financial-year-ended-2025">key metrics from the quarter</a>.
Q2 Earnings: Arm reported second-quarter revenue of $844 million, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $808.37 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The chip designer reported adjusted earnings of 30 cents per share, beating analyst estimates of 26 cents per share.
Total revenue was up 5% year-over-year, driven by record levels of royalty revenue, which was up 23% year-over-year. Royalty revenue growth was primarily driven by continued adoption of Armv9, as well as an overall smartphone market recovery.
Annualized contract value (ACV) was up 13% year-over-year to $1.25 billion. Arm said free cash flow was negative $65 million in the quarter. The company ended the period with $2.36 billion in cash, cash equivalents and short-term investments.
"Demand for our high-performance Armv9 and CSS compute platforms continues to exceed expectations, and to accelerate our licensing and royalty revenue growth. AI everywhere is generating new opportunities for the Arm compute platform from the cloud to the edge,&#8221; said&nbsp;Rene Haas, CEO of Arm Holdings.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41784504/trumps-win-sends-indices-to-record-highs-financials-small-caps-surge-bitcoin-tops-75-000-w">Trump&#8217;s Win Sends Indices To Record Highs; Financials, Small Caps Surge, Bitcoin Tops $75,000: What&#8217;s Driving Markets Wednesday?</a>
Outlook:&nbsp;Arm sees third-quarter revenue of $780 million to $830 million. The company expects third-quarter adjusted earnings to be between 23 cents and 27 cents per share versus estimates of 21 cents per share.
Arm also reiterated full-year guidance. The company continues to expect full-year revenue of $3.8 billion to $4.1 billion. Arm expects full-year adjusted earnings to be between $1.45 and $1.65 per share. 
Management will hold a conference call with analysts and investors at 5 p.m. ET. 
ARM Price Action: <a href="https://www.benzinga.com/quote/ARM" target="_blank" rel="noreferrer noopener">Arm shares</a> were down 1.85% in after-hours, trading at $142 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: Shutterstock.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Arm Holdings Q2 2025 Earnings Call &#x7C; $ARM" width="500" height="281" src="https://www.youtube.com/embed/jbop4upn9GU?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

Global

After-Hours Center

Movers

Arm Holdings Q2 Earnings: Revenue Beat, EPS Beat, AI Creating New Opportunities And More

Outlook
Over the last several months, the beauty market has maintained solid momentum, though growth has moderated from the outsized double-digit growth of the last few years. Prestige fragrances remain an outperforming category, though growth has moderated by a couple of points exiting Q1. Mass beauty is now growing in the low single digits, with flattish performance in the mass cosmetics category. Within this backdrop, slower end demand and significant channel shifts in U.S. mass beauty and in Asia, are continuing to weigh on order levels into Q2, with sell-in tracking well below sell-out. As a result of these factors, Coty expect LFL sales growth in the first half of 3-4%.
The pace of category growth and consumer demand during the critical holiday period remains the central factor influencing the outlook for the second half, including retailer inventory levels and pace of re-orders. At present, Coty anticipates LFL growth in the second half to be relatively consistent with the first half, reflecting easier prior year comparisons and solid prestige fragrance performance on the one hand, and continued pressure in the Chinese mainland, Asia Travel Retail and U.S. mass cosmetics on the other hand.
In this very dynamic beauty market environment, Coty is future proofing its organization and processes to better capture new opportunities, respond to changes in the market with more agility, and solidify Coty's position as a beauty leader over the long term. Many of the workstreams are already under way, with an acceleration now in the timing of delivery, while others are newly initiated. Through the combination of these efforts, Coty now anticipates FY25 savings of over $120 million, an increase of over $45 million versus its initial target. And importantly, these projects should continue to deliver savings in FY26 and beyond.
Through the combination of continued sales growth, continuous gross margin expansion and increased cost savings for FY25 and beyond, while maintaining A&amp;CP in the high 20s percentage, Coty expects FY25 adjusted EBITDA to grow near the lower end of its prior guidance of +9-11% YoY. This outlook includes resumed adjusted EBITDA growth in Q2 in the mid single digit percentage, with steady EBITDA growth acceleration in Q3 and Q4. This adjusted EBITDA growth target, in conjunction with continued though more moderate revenue growth, reflects an even stronger adjusted EBITDA margin expansion in FY25 of close to 100 bps, following the 30 bps adjusted EBITDA margin expansion in FY24. Coty expects FY25 adjusted EPS at the low end of its prior guidance range of $0.54-0.57, reflecting mid teens percentage growth.
Finally, Coty continues to expect FY25 free cash flow to grow by a double-digit percentage YoY to the low to mid $400M range. With the tight inventory management by retailers adding some variability on cash inflow timing, Coty remains on track to exit CY24 with leverage below 3x and continues to target leverage close to 2.5x exiting CY24.

COTY

Coty Expects FY25 Adjusted EPS At The Low End Of Its Prior Guidance Range Of $0.54-$0.57 Vs $0.55 Est.

Marathon Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.63 by 1.59 percent. This is a 16.88 percent decrease over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $1.79 billion which beat the analyst consensus estimate of $1.72 billion by 4.39 percent. This is a 1.21 percent decrease over sales of $1.81 billion the same period last year.

Marathon Oil Q3 2024 Adj EPS $0.64 Beats $0.63 Estimate, Sales $1.79B Beat $1.72B Estimate

Bumble Sees FY24 Total Revenue $1.066B-$1.072B vs $1.07B Est.

ANSS

Ansys Expects FY24 ACV Growth To Be Double-Digit

Rayonier Completes $495M Timberland Dispositions Across 200,000 Acres In Oklahoma And Washington, Enhancing Shareholder Value And Reducing Leverage To 2.8x EBITDA

Seer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEER#NASDAQ">SEER</a>) affirms FY2024 sales outlook from $13.00 million-15.00 million to $13.00 million-15.00 million.

SEER

Seer Affirms FY2024 Sales Guidance from $13.00M-15.00M to $13.00M-15.00M

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/11/2024-11-06_08h51_37.png" alt="" style="width:624px" /></figure>
<h4 class="wp-block-heading">Deploy Cash And Reduce Hedges</h4>
In addition to Trump winning the presidency, here are the key points:
<ul>
<li>Republicans have won control of the Senate.</li>
<li>Mainstream media is calling control of the House too close to call.&nbsp; However, betting markets are at a 90% probability of Republicans winning the House.</li>
<li>If Republicans win the House, there will be a complete red sweep, allowing Trump to more easily implement his agenda.</li>
<li>Trump is on track to win the popular vote. If Trump wins the popular vote, he will use that to overcome objections from Democrats.</li>
<li>The prevailing wisdom is that Trump's agenda will be highly inflationary.&nbsp; However, in The Arora Report analysis, there are several things that Trump can easily do to prevent inflation from surging again while growing the economy and bringing manufacturing back to the U.S.</li>
<li>On the other hand, if Trump embarks on a $2T cut in the Federal budget as he and Elon Musk said on the campaign trail, there is a 70% probability of a recession and the stock market falling 20% &#8211; 30%.&nbsp; Trump has said that he would appoint Musk as the efficiency czar.&nbsp; However, the probability of Trump embarking on such a program that he campaigned on is low.</li>
<li>In The Arora Report analysis, investors will need to pay attention to how Trump implements his agenda.&nbsp; The method of execution can be the difference between a 20% rise in the stock market versus a 20% drop in the stock market.&nbsp;&nbsp;</li>
</ul>
Consider deploying cash and reducing hedges.&nbsp; Consider making these moves slowly, taking advantage of opportunities that the market may present by scaling in.&nbsp; 
<h3 class="wp-block-heading">Opportunities</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-deploy-cash-investing-opportunities-spy-mc-11062024">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul>
<li>The chart shows in the early trade the stock market is technically breaking out.&nbsp; The Arora Report will be carefully watching to see if the breakout is sustained or if it fails.</li>
<li>RSI on the chart shows there is room for the stock market to run higher.</li>
<li>Investors need to be cognizant that after the initial euphoria of Trump's win wears off, there may be a ‘sell the news' reaction.</li>
<li>In The Arora Report analysis, if there is a late ‘sell the news' reaction, the dip should be bought.&nbsp;&nbsp;</li>
<li>Here are the money flows in various asset classes in the early trade after Trump's victory:
<ul>
<li>Extremely positive in the dollar</li>
<li>Extremely positive in stocks</li>
<li>Very positive in bitcoin</li>
<li>Extremely negative in bonds</li>
<li>Negative in gold</li>
<li>Negative in oil</li>
</ul>
</li>
<li>Instead of acting out of emotion, consider taking a measured approach.&nbsp; There are many short term opportunities, but they are suitable only for aggressive investors.&nbsp; There have been a number of posts in the Real Time Feeds giving signals from both the long and short sides.&nbsp; If you are not aggressive, be patient; there will be plenty of opportunities for investors who are not aggressive.</li>
<li>In addition to short term opportunities, plenty of long term opportunities are developing.&nbsp; There is no need to rush for long term opportunities.&nbsp; Consider being patient and waiting for dips in the buy zones.</li>
<li>The FOMC is meeting.&nbsp; The Fed decision is ahead and may have a significant impact on the markets.&nbsp;</li>
</ul>
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are neutral in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
In the early trade, money flows are negative in Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).
In the early trade, money flows are extremely positive in SPDR S&amp;P 500 ETF Trust (SPY) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).  The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).  The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h3 class="wp-block-heading">Bitcoin</h3>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is seeing buying.&nbsp; Crypto bulls are targeting $100,000 bitcoin in a short time.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Politics

Markets

General

$BTC

AAPL

AMZN

GOOG

MSFT

NVDA

TSLA

Deplay Cash And Reduce Hedges, Short Term Opportunities At Hand, Prepare For Long Term Opportunties

Avalo Therapeutics (AVTX) has issued an announcement. Avalo Therapeutics, Inc. has appointed the seasoned legal professional Paul Varki as their ne...

Avalo Therapeutics Welcomes New Chief Legal Officer Paul Varki

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Avalo Therapeutics (AVTX – Research Report), with a price t...

Oppenheimer Remains a Buy on Avalo Therapeutics (AVTX)

An update from Avalo Therapeutics (AVTX) is now available. Avalo Therapeutics has appointed Dr. Mittie Doyle as its new Chief Medical Officer, brin...

Avalo Therapeutics Welcomes New CMO with Competitive Package

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It could be quite beneficial to invest in personalized nutrition stocks for this month in July.



Some applications in the personalized nutrition market are now using artificial intelligence and machine learning, or ML, to provide consumers with more <a href="https://www.futuremarketinsights.com/reports/personalized-nutrition-market">targeted</a> and therefore better advice on their diet.



New algorithms and AI are being designed and individual genetic, microbiome and biometric data are being used to design diets. Advancements include DNA and blood profiling of the consumer, where specific dietary suggestions can be provided based on the individual&rsquo;s biochemistry.&nbsp;



The global consumer is becoming more health <a href="https://www.snsinsider.com/reports/personalized-nutrition-market-3878">conscious</a> and seeking preventative measures to maintain their health and wellbeing. This shift is creating a need for products and services that are related to dietary counseling as per the consumer&rsquo;s need.



In order to meet these needs, companies are now spending their money on research and development to come up with new products; this includes personal care supplements, diet and even beverages made to fit certain styles.



These are durable trends in the market that will persist, so here are three personalized nutrition stocks for investors to consider that are riding high on them.



<h2>23andMe (ME)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/01/23andme-300x169.jpg" alt="A close-up shot of the saliva collection kit from 23andMe."><div>Source: nevodka / Shutterstock.com</div></div>23andMe (NASDAQ:<a href="https://investorplace.com/stock-quotes/me-stock-quote/">ME</a>) has a huge database of customers&rsquo; genetic information. It is primarily a therapeutics company, which makes it an attractive player in personalized nutrition stocks. Despite the fact that the company&rsquo;s consumer genetics kit business has experienced some <a href="https://investors.23andme.com/news-releases/news-release-details/23andme-reports-fourth-quarter-and-full-year-fiscal-2024">declines</a>, the main value of 23andMe can be found in its 14 million customers who can help to develop transformational drugs.



23andMe has an internal pipeline of several promising therapeutics: an antibody cancer drug and a NK cell activator that is already in the clinical trials.&nbsp;



It has also expanded the rest of its consumer genetics business, which includes a recently launched set of new premium features that offer users personal health information. The company&rsquo;s use of genetic information and pharmaceutical research gives it an edge in the fast-emerging field of personalized medicine and the potential for significant future revenues.



ME stock then is one of those personalized nutrition stocks to consider, as it combines a deep understanding of genetics and personalized medicine to offer nutritional insights.



<h2>Avalo Therapeutics (AVTX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/medicines-therapeutics-300x169.png" alt="Animated image of different medications"><div>Source: Olga Kononok/Shutterstock</div></div>Avalo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/avtx-stock-quote/">AVTX</a>) is one of the best personalized nutrition stocks to consider now. Avalo is a clinical-stage biotech company, whose primary focus is to develop new therapies to manage immune dysregulation, with the goal of using the body&rsquo;s inflammatory pathways to treat various diseases.&nbsp;



The core of Avalo&rsquo;s pipeline consists of <a href="https://ir.avalotx.com/press-releases/detail/186/avalo-reports-first-quarter-2024-financial-results-and">AVTX-009</a>, a monoclonal antibody that the company claims to have a great prospect in treating hidradenitis suppurativa, or HS, a recurrent and usually painful inflammatory skin disease.&nbsp;



Avalo has high hopes for AVTX-009 based on its plans to progress it to a Phase II trial, which is expected to produce top line results in 2026.



Given that there is a large population of patients with unmet needs and a multi-billion dollar market opportunity in HS, approval of AVTX-009 may be a breakthrough in the treatment of this condition.&nbsp;



&nbsp;Of importance, Avalo has recently acquired AlmataBio and received $185 million financing. This has strengthened the company&rsquo;s capability and the company&rsquo;s cash runway into 2027. This, then, positions the company as one of those personalized nutrition stocks to buy.



<h2>Veracyte (VCYT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/10/healthy-food-300x169.jpg" alt="BSFC Stock. Healthy food including salmon, almonds, garlic, broccoli, avocado, and lettuce"><div>Source: Shutterstock.com</div></div>As one of the best personalized nutrition stocks to buy now, Veracyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcyt-stock-quote/">VCYT</a>) is a company to watch. Being a global diagnostics company that is committed to revolutionizing cancer treatment, Veracyte&rsquo;s vision on the use of personalized medicine and nutrition is appropriate, given the increasing adoption of evidence-based, patient-specific approaches to healthcare.&nbsp;



The core of Veracyte&rsquo;s strategy is the <a href="https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-first-quarter-2024-financial-results">Veracyte Diagnostics Platform</a> &mdash; a combination of genomic and clinical data, bioinformatics and AI &mdash; that allows the company to create effective cancer tests. This enables Veracyte to develop therapies new and increase its range of personalized diagnostic tests leveraging the liquid biopsy.



VCYT&rsquo;s intersection with personalized nutrition is not as direct as some of the other companies on this list, but there is a strong enough synergy here with oncology to suggest it&rsquo;s one of those stocks to watch.



VCYT has also caught the attention of analysts, with positive earnings per share <a href="https://stockanalysis.com/stocks/vcyt/forecast/">forecasts</a> on the horizon and a growing top line.



On the date of publication, Matthew Farley did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed are those of the writer, subject to the<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> InvestorPlace.com Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<div>Matthew started writing coverage of the financial markets during the crypto boom of 2017 and was also a team member of several fintech startups. He then started writing about Australian and U.S. equities for various publications. His work has appeared in MarketBeat, FXStreet, Cryptoslate, Seeking Alpha, and the New Scientist magazine, among others.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>
The post <a href="https://investorplace.com/2024/07/the-3-best-personalized-nutrition-stocks-to-buy-now/">The 3 Best Personalized Nutrition Stocks to Buy Now</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

The 3 Best Personalized Nutrition Stocks to Buy Now

Avalo Therapeutics GAAP EPS of -$14.07

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Avalo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/avtx-stock-quote/">AVTX</a>) just reported results for the second quarter of 2024.<ul><li>Avalo Therapeutics reported earnings per share of -$14.07. This was below the analyst estimate for EPS of -$6.70.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/avtx-stock-earnings-avalo-therapeutics-for-q2-of-2024/">AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q2 2024

An update from Avalo Therapeutics (AVTX) is now available. At the 2024 Annual Meeting of the Company, a significant 58% of shareholders participate...

Avalo Therapeutics Shareholders Back Board and Strategies

Oppenheimer Sticks to Their Buy Rating for Avalo Therapeutics (AVTX)

Avalo Therapeutics (AVTX) has received a new Hold rating, initiated by H.C. Wainwright analyst, Edward White. Edward White's rating is based on a c...

Cautious Outlook on Avalo Therapeutics Amid Early-Stage Development and Financial Risks

H.C. Wainwright analyst Edward White initiated coverage of Avalo Therapeutics (AVTX) with a Neutral rating and no price target The firm says the co...

Comments

Avalo Therapeutics

Avalo Therapeutics (AVTX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO